The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch

We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission in mind -- to help early clinical-stage companies like KSQ Therapeutics prepare for and enter their clinical stage on the best possible footing, ...

Om Podcasten

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Bioprocess Online and Life Science Connect and brought to you by Cytiva.